[
  {
    "ts": null,
    "headline": "Harding Loevner Global Equity’s Views on Vertex Pharmaceuticals Incorporated (VRTX)",
    "summary": "Harding Loevner, an asset management company, released its “Global Equity Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.62% gross (2.52% net) in the third quarter of 2025, compared to a 7.74% return for the MSCI All Country World Index and 7.36% gain for the MSCI […]",
    "url": "https://finnhub.io/api/news?id=1dcbd19a6a8901b6064c3128e808a84d6d02e43708e84cecf3c36bf7084553f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764858856,
      "headline": "Harding Loevner Global Equity’s Views on Vertex Pharmaceuticals Incorporated (VRTX)",
      "id": 137680221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Harding Loevner, an asset management company, released its “Global Equity Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.62% gross (2.52% net) in the third quarter of 2025, compared to a 7.74% return for the MSCI All Country World Index and 7.36% gain for the MSCI […]",
      "url": "https://finnhub.io/api/news?id=1dcbd19a6a8901b6064c3128e808a84d6d02e43708e84cecf3c36bf7084553f3"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX): Assessing Valuation After Recent Multi-Month Share Price Gains",
    "summary": "Vertex Pharmaceuticals (VRTX) has quietly added to recent gains, with shares up around 10% over the past month and roughly 17% in the past 3 months, drawing fresh attention to its long term growth story. See our latest analysis for Vertex Pharmaceuticals. At around $463 per share, Vertex’s recent 1 month share price return of nearly 10% and 3 month share price return of about 17% signal building momentum on the back of steady pipeline progress and solid earnings growth, supported by a robust...",
    "url": "https://finnhub.io/api/news?id=ad3087e97195d526e00f80e7d4766d0a99ef1e8b1a50d1424f3e7128b3e63250",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764853813,
      "headline": "Vertex Pharmaceuticals (VRTX): Assessing Valuation After Recent Multi-Month Share Price Gains",
      "id": 137680222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) has quietly added to recent gains, with shares up around 10% over the past month and roughly 17% in the past 3 months, drawing fresh attention to its long term growth story. See our latest analysis for Vertex Pharmaceuticals. At around $463 per share, Vertex’s recent 1 month share price return of nearly 10% and 3 month share price return of about 17% signal building momentum on the back of steady pipeline progress and solid earnings growth, supported by a robust...",
      "url": "https://finnhub.io/api/news?id=ad3087e97195d526e00f80e7d4766d0a99ef1e8b1a50d1424f3e7128b3e63250"
    }
  },
  {
    "ts": null,
    "headline": "Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy",
    "summary": "Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth potential. Click for this CRSP update.",
    "url": "https://finnhub.io/api/news?id=0c0fd8fef65b190bf9c8395f52f646fd5a20fb1ef943bb2877d45e24b9f1f0de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764844190,
      "headline": "Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy",
      "id": 137680924,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196575232/image_2196575232.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth potential. Click for this CRSP update.",
      "url": "https://finnhub.io/api/news?id=0c0fd8fef65b190bf9c8395f52f646fd5a20fb1ef943bb2877d45e24b9f1f0de"
    }
  }
]